Immunogenicity of therapeutic proteins. Part 2: impact of container closures.

Immunogenicity of therapeutic proteins. Part 2: impact of container closures.

Item
http://www.wikidata.org/entity/Q36751418
Pharmacy and pharmacology of biosimilars.Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars.Precipitation of a monoclonal antibody by soluble tungstenMonoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studiesEffects of shear on proteins in solution.Extractables and leachables considerations for prefilled syringes.Host cell protein testing by ELISAs and the use of orthogonal methods.Insulin biosimilars: the impact on rapid-acting analogue-based therapy.Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting.Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.Biosimilars and safety issuesBiosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council
P2860

Immunogenicity of therapeutic proteins. Part 2: impact of container closures.

Item
http://www.wikidata.org/entity/Q36751418
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Immunogenicity of therapeutic proteins. Part 2: impact of container closures.
@en
type
label
Immunogenicity of therapeutic proteins. Part 2: impact of container closures.
@en
prefLabel
Immunogenicity of therapeutic proteins. Part 2: impact of container closures.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Immunogenicity of therapeutic proteins. Part 2: impact of container closures.
@en
P2093
P304
P31
P356
10.1016/J.BIOTECHADV.2007.01.006
P433
P478
P577
P698